Spinal muscular atrophy trials in China

In China 11 Also abroad 68

11 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Where
Guangzhou, Shanghai, Zhengzhou
Age
0 days to 42 days
People
30 worldwide
Run by
Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00
No phaseTaking people
Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
Where
Beijing
Age
6 years to 12 years
People
13
Run by
Peking University Third Hospital
See details and how to joinNCT07822711
Phase 1/2Taking people
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
Where
Beijing, Hangzhou, Shanghai
Age
Up to 180 days
People
11
Run by
Lanyue Biotech (Hangzhou) Co., Ltd.
See details and how to joinNCT07554924
Phase 3Taking people
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Where
Beijing
Age
15 years to 60 years
People
90 worldwide
Run by
Biogen
See details and how to joinNCT07444476
No phaseEnrolling by invitation
GCB-001 in Treatment of Patients With Type II (SMA) Spinal Muscular Atrophy
Where
Hangzhou
Age
2 years to 12 years
People
6
Run by
Genecombio Ltd.
See details and how to joinNCT06772402
Phase 1/2Taking people
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
Where
Beijing, Shenyang, Suzhou
Age
0 months to 6 months
People
18
Run by
GeneCradle Inc
See details and how to joinNCT05824169
Phase 1/2Taking people
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
Where
Beijing
Age
2 years and over
People
21
Run by
GeneCradle Inc
See details and how to joinNCT06421831
Phase 3Taking people
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
Where
Beijing, Shanghai, Shenzhen, Suzhou, Wuhan
Age
2 years to 12 years
People
50
Run by
GeneCradle Inc
See details and how to joinNCT06971094
Early phase 1Enrolling by invitation
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
Where
Shanghai
Age
1 day to 2 years
People
4
Run by
Guangzhou Jiayin Biotech Ltd
See details and how to joinNCT06888661
No phaseEnrolling by invitation
A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
Where
Shanghai
Age
1 month and over
People
18
Run by
Guangzhou Jiayin Biotech Ltd
See details and how to joinNCT06588803
No phaseTaking people
A Registered Cohort Study on SMA
Where
Fuzhou
Age
1 week to 70 years
People
2,000
Run by
Wan-Jin Chen
See details and how to joinNCT04010604